Cardioprotective effects of minocycline against doxorubicin-induced cardiotoxicity

Naderi, Yazdan; Khosraviani, Sara; Nasiri, Saba; Hajiaghaei, Fahimeh; Aali, Ehsan; Jamialahmadi, Tannaz; Banach, Maciej; Sahebkar, Amirhossein

doi:10.1016/j.biopha.2022.114055

Cited by 10 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of this study also indicated antioxidative effects of minocycline (Figure 6 -Figure 9), where the antioxidant effect was more pronounced during postconditioning with minocycline (Figure 9). In experimental model of doxorubicin-induced cardiotoxicity, minocycline induced increase of CAT and SOD activity, as well as reduction of MDA in heart tissue [31]. These antioxidant effects were accompanied with reduced markers of heart damage (serum activity of lactate dehydrogenase (LDH) and creatine kinase MB (CK-MB)) and improvements in histopathological features of myocardium.…”

Section: Discussionmentioning

confidence: 99%

Antioxidative and Cardioprotective Effects of Minocycline in Ischemia/reperfusion Injury in Experimental Model of Hypertension

Rudic,

Stojanovic,

Sobot

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: Cardiovascular diseases remains leading cause of death and disabilities. Coronary artery occlusion and consequent ischemia leads to acute myocardial infarction, but restoration of blood flow provokes further myocardial damage known as reperfusion injury. Minocycline is possessing anti-inflammatory and anti-apoptotic activity, immune-modulating and antioxidative properties besides its primary antibacterial effect. Recently it gained significant interest in preventing cardiac damage especially due to myocardial ischemia/reperfusion injury (MI/RI). The aim of this study was to assess protective ability of preconditioning and postconditioning of isolated hearts from healthy and spontaneously hypertensive rats with minocycline, on functional recovery and redox status after MI/RI using Langendorfftechnique. Methods: Using sensor in left ventricle, the cardiodynamic parameters were recorded and in the samples of the coronary venous effluent oxidative stress biomarkers were analyzed. Minocycline was injected directly into the coronary vessels, in preconditioning 5 min before global ischemia, and in postconditioning during the first 5 min of reperfusion. Results: Changes in redox balance induced by minocycline were more pronounced in postconditioning fashion of application. Cardioprotective effects of minocycline due to MI/RI are even more pronounced in hypertensive hearts. Conclusion: Minocycline showed significant cardioprotective effects, which was more pronounced in hypertensive compared to healthy hearts. Reduction of pro-oxidative biomarkers was more pronounced in hypertensive hearts compared to the normotensive, especially if it is applied in the form of post-conditioning. The fact that better effects are achieved during postconditioning is particularly important, bearing in mind that it is not possible to predict the occurrence of a heart attack.

show abstract

Section: Discussionmentioning

confidence: 99%

Antioxidative and Cardioprotective Effects of Minocycline in Ischemia/reperfusion Injury in Experimental Model of Hypertension

Rudic,

Stojanovic,

Sobot

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Huang et al conducted an experiment in which they depleted the gut microbiota using antibiotics and found that this intervention could alleviate DIC [ 88 ]. Furthermore, a recent study demonstrated that minocycline could improve DIC by reducing inflammation and oxidative stress [ 158 ]. However, some studies have indicated that Abs-induced gut microbiota dysbiosis exacerbates the disease [ 159 , 160 ].…”

Section: The Potential Interventions Of Microbiota-targeted Therapeut...mentioning

confidence: 99%

Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions

Huang,

Li,

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Doxorubicin (DOX) is a broad-spectrum and highly efficient anticancer agent, but its clinical implication is limited by lethal cardiotoxicity. Growing evidences have shown that alterations in intestinal microbial composition and function, namely dysbiosis, are closely linked to the progression of DOX-induced cardiotoxicity (DIC) through regulating the gut-microbiota-heart (GMH) axis. The role of gut microbiota and its metabolites in DIC, however, is largely unelucidated. Our review will focus on the potential mechanism between gut microbiota dysbiosis and DIC, so as to provide novel insights into the pathophysiology of DIC. Furthermore, we summarize the underlying interventions of microbial-targeted therapeutics in DIC, encompassing dietary interventions, fecal microbiota transplantation (FMT), probiotics, antibiotics, and natural phytochemicals. Given the emergence of microbial investigation in DIC, finally we aim to point out a novel direction for future research and clinical intervention of DIC, which may be helpful for the DIC patients.

show abstract

“…Several strategies have been developed to prevent anthracycline-related cardiotoxicity, including administration alternatives (liposomal, continuous infusion) and the use of cardioprotective drugs according to the 2017 American Society of Clinical Oncology (ASCO) and the 2020 European Society for Medical Oncology (ESMO) guidelines [8][9][10]. These drugs include dexrazoxane, angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blocker (ARB), and beta-blockers [10].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and harms associated with beta-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis.

Li,

Duddy,

Cardona

et al. 2024

Arch Med Sci

View full text Add to dashboard Cite

IntroductionIn patients with breast cancer and lymphoma, anthracyclines are associated with early and late dose-related cardiotoxicity. We systematically evaluated efficacy and harms of the use of beta-blockers in breast cancer and lymphoma patients undergoing chemotherapy.Material and methodsWe searched five engines, and pre-prints until October 10, 2022, for randomised controlled trials (RCTs) evaluating beta-blockers for anthracycline-associated cardiotoxicity in breast cancer and lymphoma patients. Primary outcomes were all-cause mortality, left ventricular ejection fraction (LVEF), left ventricular end-diastolic and end-systolic diameter (LVEDD, LVESD), peak E’ velocity, E/A ratio, E/e’ ratio, NT-pro BNP levels. Secondary outcome was heart rate. Inverse variance random effect meta-analyses were performed, and we used GRADE methods to assess quality of evidence (QoE).ResultsTwelve RCTs were selected (n=1,794), seven RCTs evaluated carvedilol. Mean ages were 39 to 52 years-old, 88.5% were women; 79.4% had breast cancer, and 11.5% lymphoma. The evidence was very uncertain about the effect of beta-blockers on all-cause mortality (RR 0.87, 95%CI 0.55 to 1.37, 12 RCTs, I2=0%, very low QoE), LVEF (MD 2.73%, 95%CI -0.45% to 5.92%, 12 RCTs, I2=93%, very low QoE), and heart rate (MD -9.14 bpm, 95%CI -15.02 to -3.26, two RCTs, I2=87%, very low QoE) vs. controls. Beta-blockers likely reduced NT-pro BNP levels slightly (MD -15.35 pg/mL, 95%CI -22.39 to -8.31, two RCTs, I2=0%, moderate QoE). There were no effects on other outcomes, all with very low QoE.ConclusionsProphylactic use of beta-blockers for cardioprotection had little to no effect on all-cause mortality, LVEF or cardiac function outcomes in cancer patients undergoing anthracycline therapy.

show abstract

Cardioprotective effects of minocycline against doxorubicin-induced cardiotoxicity

Cited by 10 publications

References 46 publications

Antioxidative and Cardioprotective Effects of Minocycline in Ischemia/reperfusion Injury in Experimental Model of Hypertension

Antioxidative and Cardioprotective Effects of Minocycline in Ischemia/reperfusion Injury in Experimental Model of Hypertension

Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions

Efficacy and harms associated with beta-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis.

Contact Info

Product

Resources

About